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Abstract
Bernard-Soulier syndrome (BSS), also known as Hemorrhagiparous thrombocytic dystrophy, is a
hereditary bleeding disorder affecting the megakaryocyte/platelet lineage and characterized by
bleeding tendency, giant blood platelets and low platelet counts. This syndrome is extremely rare
as only ~100 cases have been reported in the literature. Clinical manifestations usually include
purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding. The syndrome is transmitted
as an autosomal recessive trait. The underlying defect is a deficiency or dysfunction of the
glycoprotein GPIb-V-IX complex, a platelet-restricted multisubunit receptor required for normal
primary hemostasis. The GPIb-V-IX complex binds von Willebrand factor, allowing platelet
adhesion and platelet plug formation at sites of vascular injury. Genes coding for the four subunits
of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21,
respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5. Diagnosis is
based on a prolonged skin bleeding time, the presence of a small number of very large platelets
(macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent
expression of the GPIb-V-IX complex. Prothrombin consumption is markedly reduced. The
prognosis is usually good with adequate supportive care but severe bleeding episodes can occur
with menses, trauma and surgical procedures. Treatment of bleeding or prophylaxis during surgical
procedures usually requires platelet transfusion.
Disease name and synonyms
Bernard-Soulier syndrome (BSS)
Hemorrhagiparous thrombocytic dystrophy
Congenital hemorrhagiparous thrombocytic dystrophy
Definition and diagnostic criteria
The Bernard-Soulier syndrome (BSS) is an autosomal
recessive disease associated with bleeding tendency, giant
blood platelets and low platelet counts. The defect is
restricted to the megakaryocyte/platelet lineage.
Congenital platelet disorders are often difficult to distin-
guish on the basis of clinical manifestations and require
specialized laboratory tests. Functional analysis of platelet
suspensions by aggregometry is needed to differentiate
BSS from other rare inherited disorders accompanied by
macrothrombocytopenia, such as the May-Hegglin,
Sebastian, Fechtner and Epstein's syndromes [1]. A firm
diagnosis calls for conjunction of increased bleeding
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times, macrothrombocytopenia, defective ristocetin-
induced agglutination and low or absent levels of platelet
GPIb-V-IX (CD42a-d) by flow cytometry.
Epidemiology
This syndrome is extremely rare as only ~100 cases have
been reported in published articles, mostly in the popula-
tions of Japan, Europe, and North America. Prevalence
has been estimated at less than 1/1,000,000 but is proba-
bly higher due to misdiagnosis and underreporting. This
low frequency could probably be explained by the fact
that the affected genes are very compact being interrupted
by only 1 or 2 introns.
Clinical description
In 1948, Jean Bernard and Jean-Pierre Soulier [2], two
French hematologists, described a young male patient
who had a severe bleeding defect with a prolonged bleed-
ing time, a low platelet count with very large platelets
(macrothrombocytopenia). In view of these defects, they
named the disorder "Dystrophie thrombocytaire-hémor-
ragipare congénitale" (Hemorrhagiparous thrombocytic
dystrophy). Additional cases presenting with an identical
disorder, mostly transmitted as an autosomal recessive
trait and often associated with consanguinity, have been
subsequently reported [3,4]. In the literature, the disease
is now commonly referred to as Bernard-Soulier syn-
drome (BSS). In most cases, bleeding symptoms manifest
rapidly after birth or during early childhood. Clinical
manifestations usually include purpura, epistaxis, gingival
bleeding and menorrhagia, and more rarely gastrointesti-
nal bleeding and hematuria. Severe bleeding episodes are
associated with trauma and surgical procedures such as
tonsillectomy, appendectomy, splenectomy, or occur dur-
ing dental extractions and menses. However, the severity
and frequency of bleeding vary between individuals.
Bleeding mainly affects mucocutaneous tissues, and
major hematomas are very rarely observed.
Etiology
Defects in three genes give rise to the typical clinical fea-
tures and platelet anomalies associated with BSS. This is
due to the multisubunit nature of the affected GPIb-V-IX
receptor, whose structure is shown in Figure 1. The main
function of the GPIb-V-IX complex is to ensure normal
primary hemostasis by initiating platelet adhesion at sites
of vascular injury [5]. Adhesion is brought by its binding
to von Willebrand factor, itself captured from plasma by
subendothelial collagen [6]. Four distinct transmembrane
proteins, GPIbα (MW 135 kDa), GPIbβ (MW 26 kDa),
GPIX (MW 20 kDa) and GPV (MW 82 kDa) assemble to
form the functional receptor at the surface of bone mar-
row megakaryocytes, the precursors of mature circulating
platelets [7]. GPIbα, GPIbβ, and GPIX are closely associ-
ated and are all required for efficient biosynthesis of the
receptor [8]. A lack of a single subunit dramatically
decreases surface expression of the whole complex. GPV is
more loosely associated and its absence does neither pre-
vent expression, nor von Willebrand factor binding func-
tion. The four subunits are separately encoded by genes
mapping to chromosomes 17p12 (GPIBA), 22q11.2
(GPIBB), 3q29(GP5) and 3q21 (GP9) [9-15]. The four
genes belong to the leucine-rich family of proteins and are
exclusively expressed in platelets under physiological con-
ditions. They have a simple structure with the coding
sequence contained within a single exon, except for GPIBB
which contains an intron of 10 bases after the start codon.
To date, 47 different genetic defects associated to the BSS
have been identified [see Additional file 1]. A Bernard-
Soulier registry can also be found at Bernard-Soulier syn-
drome web site [16]. Defects are due to mutations in
GPIBA (20 mutations), which is the largest subunit and
bears the von Willebrand binding site, in GPIBB  (16
mutations) and in GP9 (11 mutations). The defects can be
separated into three major classes: 1) missense mutations
or short in-frame deletions which rarely give rise to nor-
mal or slightly decreased expression of a dysfunctional
receptor or more often to an abnormal/unstable complex
with strongly decreased surface expression; 2) nonsense
mutations resulting in smaller subunits that typically lack
the transmembrane domain; 3) frameshift insertions or
deletions leading to a novel polypeptide sequence and
often to a premature stop. In very few cases, a single muta-
tion, like in some GPIbα  and GPIX mutants, affects
mainly the function of the receptor, which is at least par-
tially expressed in giant platelets. Most of the defects are
unique to a single individual or family. One exception is
the GP9 Asn45Ser mutation, which has been reported in
The platelet GPIb-V-IX complex Figure 1
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several families from different countries, probably as a
result of a founder effect [17]. The Ala156Val mutation
also occurs frequently in the Italian population, with an
apparent dominant transmission leading to macrothrom-
bocytopenia in heterozygote individuals [18]. Several
mutations combining a BSS phenotype and the DiGeorge/
Velo-cardio-facial syndrome (VCF) have been reported. In
these cases, one allele carried a mutated GPIBB  gene,
while the other allele had the large deletion of the chro-
mosomal region 22q11.2, containing the GPIBB  gene,
typical of the Di George/VCF defect [19].
Several polymorphisms have been reported especially in
the GPIBA gene. They include silent mutations, a missense
mutation which gives rise to an alloantigen and a variable
number of tandem repeat (VNTR) polymorphism [20]. To
date, none of these polymorphisms have been linked to
anomalies in receptor expression or function.
Rare gain of function mutations of GPIBA  give rise to
platelet-type von Willebrand disease, a clinical entity dis-
tinct from BSS. The condition resembles type IIB von Wil-
lebrand disease due to clearance of plasma von
Willebrand factor by aggregated platelets. Three missense
mutations in a disulfide loop flanking the leucine-rich
domain and a 9 amino acid deletion in the macroglyco-
peptide have been reported in these patients [21-24].
Diagnostic methods
Skin bleeding times in BSS are moderately (5–10 min) to
severely (>20 min) prolonged. A constant feature is the
presence of a small number of very large platelets with a
rounded shape (main volume 11–16 μm3; diameter 4–10
μm). The initial laboratory test should therefore include
blood cell counts and examination of blood smears. Plate-
let counts typically range from 20,000 to 100,000/μl.
Manual counting is required for an accurate determina-
tion as the very large platelets in BSS are often mistaken
for lymphocytes in automatic counters. The distinctive
abnormality of BSS platelets is an isolated defect in ris-
tocetin-induced agglutination. Unlike the defect in von
Willebrand disease, this anomaly is not corrected by the
addition of normal plasma. Levels of FVIII-von Wille-
brand complex are assessed. Aggregation responses to
agonists such as ADP or collagen are normal, however
decreased responses to thrombin can be observed. A
marked defect in prothrombin consumption is constantly
observed and may be useful for the diagnosis: it is attrib-
uted to a defective binding of FXI due to a lack of GPIb
[25], and to a decrease in GPIb-fibrin-dependent
thrombin generation [26,27]. Flow cytometry analysis
using a panel of specific monoclonal antibodies (CD42 a-
d) will confirm this diagnosis. Additional tests in special-
ized research units may include platelet glycoprotein anal-
ysis by SDS-polyacrylamide gel separation and
immunoblotting, and finally, study of genetic abnormali-
ties.
Differential diagnosis
BSS belongs to a heterogeneous group of rare inherited
diseases characterized by a reduced number of platelets
(thrombocytopenia). A published diagnostic algorithm
should facilitate differential diagnosis of BSS [28]. For
example, presence of small platelets is typical of Wiscott-
Aldrich syndrome and X-linked thrombocytopenia. Giant
platelets associated with neutrophil inclusions will orient
toward MYH9-related diseases (May-Hegglin, Sebastian,
Fechtner, and Epstein syndromes). Other parameters will
help diagnose macrothrombocytopenia in Di George,
Gray platelet, Montreal and Paris-Trousseau syndromes.
Finally, some cases of heterozygous BSS can also exhibit
macrothrombocytopenia.
BSS is difficult to be distinguished on the basis of clinical
manifestations only and has often been misdiagnosed as
idiopathic thrombocytopenic purpura (ITP), an immuno-
logical disorder, and treated unsuccessfully with steroids
or splenectomy.
Genetic counseling
Genetic counseling should follow the standards estab-
lished for all autosomal recessive diseases.
Antenatal diagnosis
Prenatal diagnosis is theoretically feasible when the
genetic defect has been identified in a particular kindred.
This is probably not justified as the syndrome rarely gives
rise to life threatening bleeding. With a good prophylaxis,
a fairly normal quality of life can be maintained. In addi-
tion, cord blood or chorion villus sampling bear a high
risk of bleeding and premature abortion.
Management
Therapeutic approaches include both general and specific
treatment of bleeding. Patients should be warned to avoid
traumas, antiplatelet medication such as aspirin, to main-
tain adequate dental hygiene and to use contraceptive in
female at puberty. Treatment of bleeding or prophylaxis
during surgical procedures usually requires blood or
platelet transfusion with the associated risk of developing
antiplatelet alloantibodies. Desmopressin and rFVIIa
administration have been shown to shorten the bleeding
time in some patients. In rare cases of patients with life-
threatening disorders, bone-marrow or umbilical-cord
hematopoietic stem cell transplantation may be consid-
ered [29]. As a rather simple genetic defect, BSS could be
a candidate for future gene replacement therapy using
virally transduced megakaryocyte progenitors.Orphanet Journal of Rare Diseases 2006, 1:46 http://www.OJRD.com/content/1/1/46
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Prognosis
With a good education, adequate care and prevention of
trauma, patients can live a fairly normal life. Nevertheless,
possible occurrence of severe bleeding in case of trauma
and surgical intervention should always be kept in mind
and treated adequately.
Unresolved questions
To date, no BSS patient has been identified with a muta-
tion of the GPV subunit but existence of such defects can-
not be ruled out, and they could potentially result in
variant or mild forms of BSS.
As for other platelet deficiencies, it is difficult to correlate
genetic defects with propensity to bleed and severity of
bleeding.
The molecular and cellular mechanisms responsible for
the several platelet defects encountered in BSS are still
largely unknown. An explanation for their enlarged plate-
lets and low platelet counts is probably related to defec-
tive megakaryocytopoiesis but such studies are difficult to
conduct in BSS patients. Additionally, platelet functional
studies  in vivo and evaluation of a putative protection
against thrombosis are not amenable in BSS patients.
Finally, there is no clear explanation for the abnormal
prothrombin consumption in this pathology. Mouse
models of BSS are now available with deletions of the
GPIbα or GPIbβ subunit which should help answering
these remaining questions.
Additional material
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